Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer

A Phase II Trial of the NSABP Foundation Research Group, FB-5

John W. Smith, Marc E. Buyse, Priya Rastogi, Charles E. Geyer, Samuel A. Jacobs, Erica J. Patocskai, André Robidoux, Alison K. Conlin, Bilal Ansari, George P. Keogh, Philip J. Stella, Howard M. Gross, Raymond S. Lord, Jonathan A. Polikoff, Celine Mauquoi, Eleftherios P. Mamounas, Sandra M. Swain, Norman Wolmark

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Micro-Abstract We conducted a phase II study in patients with HER2-positive locally advanced breast cancer or pathologic stage 3 breast cancer. Patients received epirubicin with cyclophosphamide followed by docetaxel. Targeted therapy with trastuzumab and bevacizumab were administered for 1 year. The pathologic complete response was comparable with other chemotherapy regimens and the high recurrence-free survival and overall survival are of interest in these high-risk populations.

Original languageEnglish (US)
Pages (from-to)48-54.e3
JournalClinical Breast Cancer
Volume17
Issue number1
DOIs
StatePublished - Feb 1 2017

Fingerprint

docetaxel
Epirubicin
Neoadjuvant Therapy
Cyclophosphamide
Breast Neoplasms
Survival
Research
Recurrence
Drug Therapy
Therapeutics
Population
Bevacizumab
Trastuzumab

Keywords

  • Neoadjuvant chemotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer : A Phase II Trial of the NSABP Foundation Research Group, FB-5. / Smith, John W.; Buyse, Marc E.; Rastogi, Priya; Geyer, Charles E.; Jacobs, Samuel A.; Patocskai, Erica J.; Robidoux, André; Conlin, Alison K.; Ansari, Bilal; Keogh, George P.; Stella, Philip J.; Gross, Howard M.; Lord, Raymond S.; Polikoff, Jonathan A.; Mauquoi, Celine; Mamounas, Eleftherios P.; Swain, Sandra M.; Wolmark, Norman.

In: Clinical Breast Cancer, Vol. 17, No. 1, 01.02.2017, p. 48-54.e3.

Research output: Contribution to journalArticle

Smith, JW, Buyse, ME, Rastogi, P, Geyer, CE, Jacobs, SA, Patocskai, EJ, Robidoux, A, Conlin, AK, Ansari, B, Keogh, GP, Stella, PJ, Gross, HM, Lord, RS, Polikoff, JA, Mauquoi, C, Mamounas, EP, Swain, SM & Wolmark, N 2017, 'Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5', Clinical Breast Cancer, vol. 17, no. 1, pp. 48-54.e3. https://doi.org/10.1016/j.clbc.2016.07.008
Smith, John W. ; Buyse, Marc E. ; Rastogi, Priya ; Geyer, Charles E. ; Jacobs, Samuel A. ; Patocskai, Erica J. ; Robidoux, André ; Conlin, Alison K. ; Ansari, Bilal ; Keogh, George P. ; Stella, Philip J. ; Gross, Howard M. ; Lord, Raymond S. ; Polikoff, Jonathan A. ; Mauquoi, Celine ; Mamounas, Eleftherios P. ; Swain, Sandra M. ; Wolmark, Norman. / Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer : A Phase II Trial of the NSABP Foundation Research Group, FB-5. In: Clinical Breast Cancer. 2017 ; Vol. 17, No. 1. pp. 48-54.e3.
@article{1e038a83b3404455a0b57b55c4180d39,
title = "Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5",
abstract = "Micro-Abstract We conducted a phase II study in patients with HER2-positive locally advanced breast cancer or pathologic stage 3 breast cancer. Patients received epirubicin with cyclophosphamide followed by docetaxel. Targeted therapy with trastuzumab and bevacizumab were administered for 1 year. The pathologic complete response was comparable with other chemotherapy regimens and the high recurrence-free survival and overall survival are of interest in these high-risk populations.",
keywords = "Neoadjuvant chemotherapy",
author = "Smith, {John W.} and Buyse, {Marc E.} and Priya Rastogi and Geyer, {Charles E.} and Jacobs, {Samuel A.} and Patocskai, {Erica J.} and Andr{\'e} Robidoux and Conlin, {Alison K.} and Bilal Ansari and Keogh, {George P.} and Stella, {Philip J.} and Gross, {Howard M.} and Lord, {Raymond S.} and Polikoff, {Jonathan A.} and Celine Mauquoi and Mamounas, {Eleftherios P.} and Swain, {Sandra M.} and Norman Wolmark",
year = "2017",
month = "2",
day = "1",
doi = "10.1016/j.clbc.2016.07.008",
language = "English (US)",
volume = "17",
pages = "48--54.e3",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer

T2 - A Phase II Trial of the NSABP Foundation Research Group, FB-5

AU - Smith, John W.

AU - Buyse, Marc E.

AU - Rastogi, Priya

AU - Geyer, Charles E.

AU - Jacobs, Samuel A.

AU - Patocskai, Erica J.

AU - Robidoux, André

AU - Conlin, Alison K.

AU - Ansari, Bilal

AU - Keogh, George P.

AU - Stella, Philip J.

AU - Gross, Howard M.

AU - Lord, Raymond S.

AU - Polikoff, Jonathan A.

AU - Mauquoi, Celine

AU - Mamounas, Eleftherios P.

AU - Swain, Sandra M.

AU - Wolmark, Norman

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Micro-Abstract We conducted a phase II study in patients with HER2-positive locally advanced breast cancer or pathologic stage 3 breast cancer. Patients received epirubicin with cyclophosphamide followed by docetaxel. Targeted therapy with trastuzumab and bevacizumab were administered for 1 year. The pathologic complete response was comparable with other chemotherapy regimens and the high recurrence-free survival and overall survival are of interest in these high-risk populations.

AB - Micro-Abstract We conducted a phase II study in patients with HER2-positive locally advanced breast cancer or pathologic stage 3 breast cancer. Patients received epirubicin with cyclophosphamide followed by docetaxel. Targeted therapy with trastuzumab and bevacizumab were administered for 1 year. The pathologic complete response was comparable with other chemotherapy regimens and the high recurrence-free survival and overall survival are of interest in these high-risk populations.

KW - Neoadjuvant chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=85008698622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008698622&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2016.07.008

DO - 10.1016/j.clbc.2016.07.008

M3 - Article

VL - 17

SP - 48-54.e3

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 1

ER -